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1. Introduction 
Blood transmitted infection is the commonest cause of death after blood transfusion. All 
patients on regular packed cell volume (PCV) or any blood component are at increased risk 
of transfusion transmitted infections. The etiological agents can be virus, bacteria or 
protozoa. These organisms can cause clinical sickness in recipient, can persist in him as 
carrier state or can cause asymptomatic infection in him. Every blood bank follows 
screening procedures to prevent such infections but the infective agents escape detection 
due to window period – a period where in the infective agent’s presence cannot be detected, 
though it is present in donor’s blood. Blood banks in developed countries are doing Nucleic 
Acid Amplification Testing (NAT) since 1999 to screen donated blood. The window period 
for testing for HIV, Hepatitis B and Hepatitis C has been significantly reduced with NAT. 
NAT can detect low levels of viral genetic material in blood. 
Patients having thalassemia major or any other chronic hemolytic anemia are on regular 
PCV infusion essential for their survival. Patients having hemophilia; on cryoprecipitate, 
fresh frozen plasma or on plasma based factors are also at increased risk. Hemophilia 
patients on recombinant factors VIII or IX, from the start of therapy are safe. 
2. Nuclear acid amplification testing (NAT) 
Despite improvement in HIV, HCV and HBV serological tests, we still have viral 
transmission of these diseases because of donations that take place while donor is: 
1. In pre-seroconversion window period 
2. Infected with immunovariant viruses 
3. A non-sero-converting chronic carrier 
In most countries, the safety of blood is ensured by donor selection, testing of donations for 
viral markers and in the case of blood products, the inclusion of viral inactivation steps 
during the manufacture of the blood products. However, transmission of HIV, HBV and 
HCV, continues to be a threat to safe blood transfusion, especially in developing countries. It 
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is due to low numbers of voluntary donations, use of low sensitivity tests for viral screening 
and the high prevalence of these viruses. This has contributed to the high rate of transfusion 
transmitted infections compared with developed countries. In developing countries, where 
the majority of donors are still replacement donors, the risk of transfusion transmitted viral 
infections is much higher than in countries with a 100% voluntary donor base. The 
prevalence of post transfusion HBV and HCV in India is between 1 to 5% [Singh, 1999]. The 
prevalence of HIV varies from region to region in a country. 
The implementation of nucleic acid testing (NAT) over the last decade into the blood 
screening process has added an extra layer of safety against transmission of transfused 
viral infections. NAT was first introduced by the European plasma industry in 1995 and 
consequently for whole blood donation screening in some parts of Europe and then Asia. 
HCV NAT was first introduced between 1999 and 2001 in blood banks across France, 
Germany, Italy, Spain, Switzerland and the United Kingdom presumably as it was 
already mandatory for plasma screening in these countries [Pathak & Chandrashekhar, 
2010]. 
Serological screening of blood donor have greatly reduced, but not eliminated the risk of 
transmission of viral infections by transfusion of blood and blood products. Production of 
antibodies takes several weeks after the infection. During this serological window period, 
infective antigen is present in blood of the patient, but there are no detectable antibodies. 
The primary benefit of NAT is the ability to reduce residual risk of infectious window 
period (WP) donations [Wiedemann et al., 2007]. 
NAT screening reduces window period as follows: 
1. HIV - 11 Days 
2. HBV - 20 Days 
3. HCV - 15 Days 
The introduction of Nucleic Acid Technology testing has reduced the risk of transfusion 
transmitted HCV and HIV infections to approximately 1 in 1 million and 1 in 3 million 
respectively in Western Europe and the USA. NAT testing can detect even low level of viral 
genetic material. 
3. Etiology of blood transmitted infections 
1. Viruses – HIV 1 & 2 virus, Hepatitis C, Hepatitis B, Other Hepatitis Viruses, 
Cytomegalovirus, Human T-Cell Leukemia Virus, Cytomegalovirus, Parvovirus, Epstein 
Barr  virus, Human herpes virus, West Nile virus. 
2. Bacterial contamination – Staphylococcus, streptococcus, Yersinia, Serratia, Acinetobacter, 
Pseudomonas, Escherichia etc. 
3. Protozoa – Malaria, Chagas, Toxoplasmosis, Leishmaniasis, Babesiosis 
4. Nematodes – Microfilariasis 
4. Transfusion transmited viral infections 
In last 2 decades, much attention has been given to prevention of viral infections like HIV-1 
and 2, human T-cell lymphotropic virus (HTLV) I and II, hepatitis C virus, hepatitis B virus 
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(HBV) and west Nile virus (WNV). Because of potential transmission of virus during 
‘immunological window period’, NAT is being performed. However, it has some limitations 
in blood components with very low levels of viremia, which can even escape detection by 
NAT. Despite this limitation, the combination of both serological testing and NAT has 
considerably reduced the risk of viral transmission by blood transfusion. 
4.1 HIV 
Human immune deficiency virus (HIV) is an important global public health problem. HIV 
infection causes a broad spectrum disease and has a varied clinical course, from mild, flu-
like symptoms to AIDS; which is life threatening and the end stage of HIV infection. HIV is 
transmitted through sexual contact, sharing of HIV contaminated needles and/or syringes, 
transfusion of blood components, and nosocomial exposure to HIV contaminated blood or 
bodily fluids, and can be passed vertically from a mother to her infant. 
Factors that can contribute to HIV transmission through blood transfusion include the 
window period (i.e. a short viraemic period in which the donor is infected with HIV at a 
very early stage and often tested negative in a donor screening test), HIV-antibody negative 
chronic carriers and HIV mutant infection. The primary source of transfusion transmitted 
HIV infection, however, is donations collected during the window period. Donated blood is 
tested for antibodies to HIV-1, HIV-1 p24 antigen test and HIV RNA test using NAT. 
Window period has been reduced from 42 days by HIV antibody assays in the 1980s to 16 
days by HIV-1 p24 antigen test and 11 days by HIV NAT [Canadian Blood Services, 2001; 
Public Health Agency of Canada, 2003]. The risk of HIV transmission through blood 
transfusion was estimated to be 1 in 752,000 donations between 1987 and 1996. This risk has 
been estimated to be 1 in 1.3 million donations following the implementation of HIV-1 p24 
testing, and 1 in 1.6 million donations following the implementation of HIV NAT on a pool 
of 24 samples. 
4.2 HCV 
Hepatitis C virus currently affects over four million people in USA. There it is the 
commonest transfusion transmitted infection and main indication for liver transplantation. 
High risk group is constituted by those who received transfusion prior to 1991 or the ones 
who were IV drug abusers using shared needles. Incubation period can be as long as 
decades and this contributes to high rate of infection. Route of infection is by and large 
intravenous/injection pricks. Sexual transmission is also possible. Other routes are 
nosocomial exposure to contaminated blood and body fluids and mother to child 
transmission. Hepatitis C virus subtype varies worldwide. Approximately 90% of 
individuals infected with HCV are either asymptomatic or have only mild symptoms. 
However, about 80% of acute infections progress to chronic infection, and almost half of 
those chronically infected individuals eventually develop cirrhosis or hepatocellular 
carcinoma after a few decades [Public Health Agency of Canada 2003]. 
In Europe, predominant genotypes are 1, 2 and 3. Types 1a and 3a are seen in north-western 
countries, whereas 1b is in Hungary, Germany, Russia and Turkey. Types 1a and 1b are 
common in North America. Types 1b, 2a and 2b predominate in Japan [Blood Book, 2011]. 
After infection, antibodies against Hepatitis C virus take 54-192 days to appear. The window 
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period yielded with HCV nucleic acid amplification testing (HCV NAT) is shorter than that 
from the HCV antibody test. There is high risk of transfusion transmitted infection in this 
window. In United States there is 1 in 121,000 risk of HCV infection. 
4.3 HBV 
Hepatitis B surface antigen testing was introduced in 1970’s and its transmission was 
consistently reduced since then. Still 300 million individuals are infected worldwide. HBV 
surface antigen is routinely included in donor screening but it fails to detect presence of 
HBV during window period. Chronic carriers of HBV may have low level viremia and may 
not have detectable HBsAg level, so some centres have started testing antibodies against 
HBV core protein (anti HBc). Today, the residual risk of transfusion transmitted HBV 
infection varies between 0.75 per million blood donations in Australia, 3.6 – 8.5 in the USA 
and Canada, 0.91 – 8.7 in Northern Europe, 7.5 – 13.9 in Southern Europe up to 200 per 
million donations in Hong Kong, largely reflecting the global epidemiology of HBV. Some 
countries with low level prevalence of HBV have implemented HBV NAT testing in plasma 
pools. The kinetics of viral antigen and antibody appearance during HBV infection create 
two different window periods in which one or the other test may fail: the "early acute 
phase", when serological markers are still negative and the "late chronic phase" when 
HBsAg may become gradually undetectable, although infectivity remains. NAT can 
potentially identify and can be of particular benefit in detecting HBV DNA in latent HBV 
infection in early acute phase/occult HBV infection, when HBV DNA is present in plasma 
and presence of anti-HBC and HBsAg is variable [Biswas et al., 2003].   
4.4 Hepatitis A virus 
Hepatitis A is an important vaccine preventable infectious disease. The most common mode 
of transmission is feco-oral. It occurs through personal contact or ingestion of contaminated 
food/water. 
Transmission of HAV through blood transmission is not yet established. However, 
transmission of HAV has been reported through infusion of blood products in hemophilia 
patients. Since pooled plasma from multiple donors is used for preparing blood products, 
and the solvent-detergent method for viral inactivation is ineffective against HAV, the risk 
of transmission of HAV through the use of blood products, though extremely small, may 
still exist. Currently, blood units are not routinely tested for antibodies to HAV. It has been 
suggested that recipients of clotting factors receive vaccine against HAV to prevent 
Transfusion Transmitted hepatitis A [Moor et al., 1999]. 
4.5 Hepatitis E virus (HEV) 
It’s an acute infection caused by hepatitis E virus and is endemic in Asia and Africa. Mode 
of transmission as well as clinical presentation is same as in hepatitis A. Like hepatitis A, 
there are no carriers in hepatitis E. Periods of viremia are also short. 
Although transmission of HEV through blood transfusion has not been established, 
possibility of its transmission through transfusion cannot be excluded in endemic areas. 
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5. Other hepatitis viruses 
Other transfusion transmitted viruses – TTV, SEN-V and GBV-C do not cause hepatitis or 
other diseased states. Routine screening before blood transfusion is not recommended 
[Dzieczkowski & Anderson, 2008]. 
5.1 Human T Lymphotropic virus (HTLV) 
HTLV 1 is associated with adult T cell leukemia/lymphoma and severe tropical spastic 
paraparesis. HTLV 2 is associated with milder forms of myelopathy / spastic paraparesis 
and pulmonary disorders. Both retroviruses have also been attributed a role in risk for 
developing severe asthma, respiratory and urinary tract infections, uveitis and dermatitis 
[Murphy et al., 1994, 2004]. Enzyme immunosorbent assays and particle agglutination tests 
are used for screening, followed by confirmatory tests of positive tests. No vaccine is 
available for prophylaxis and no effective antiviral drug is available for treatment. 
5.2 Cytomegalovirus (CMV) 
This omnipresent virus infects more than half of general population. Prevalence of CMV 
antibodies increases with age. Acute infection is usually asymptomatic. This is 
transmitted by infected WBC’s found in packed red cells or platelet components. 
Leukoreduction reduces the risk of CMV transmission, regardless of serological status of 
donor. Immunocompromised patients, CMV seronegative transplant recipients, pregnant 
women and neonates form the high risk group. Pre-storage leukodepletion of blood 
components may be as effective as the use of CMV seronegative blood components 
[Vamvakas, 2005; Blajachman et al., 2001; Blajachman, 2006]. Donor blood is not routinely 
tested for CMV. 
5.3 Parvovirus B-19 
Blood components as well as pooled plasma products can transmit parvovirus B-19. Patients 
having thalassemia or hemophilia are at risk. Infection can also be transmitted through 
respiratory secretions as well vertically from mother to child. This is etiological agent of 
erythema infectiosum, or 5th disease in children. Patient may remain asymptomatic or 
present with mild symptoms like fever. Parvovirus B-19 has affinity for erythroid precursors 
and in some patients, inhibits both production and maturation of erythrocytes 
[Dzieczkowski & Anderson, 2008]. Patient can develop pure red cell aplasia or develop 
acute aplastic crisis in patients having hemolytic anemia like sickle cell disease or 
thalassemia. Infection of a seronegative pregnant mother may result in fetal anemia and/or 
fetal death. 
The prevalence of antibodies to HPV-B19 among blood donors seems to be very low. 
Currently, blood units are not routinely screened for serologic markers of HPV-B19 
infection, and the viral inactivation methods are ineffective against HPV-B19 [Koenigbauer 
et al., 2000]. Therefore, a very low risk of HPV-B19 transmission through blood transfusion, 
in particular through the infusion of blood products, may exist. It has also been suggested 
that high-risk individuals receive anti-HPV-B19 negative blood components in order to 
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prevent/reduce severe complications associated with HPV-B19 infection [Wu et al., 2005; 
Plentz et al., 2005]. 
5.4 Epstein-Barr virus (EBV) 
Epstein-Barr virus is common in general population. In children, infection is usually 
asymptomatic, whereas in adults, it often results in mild symptoms like fever and sore 
throat. EBV is generally associated with Burkitt’s lymphoma, nasopharyngeal carcinoma 
and B-cell lymphoma in immune-compromised patients. 
It is transmitted primarily through person to person contact via saliva. It is also transmitted 
through blood transfusion. Since antibodies to EBV are present in up to 90% of population, 
it would be impractical to eliminate sero-positive donors by serological screening tests. 
Leukodepletion remains best option to reduce EBV transmission through blood transfusion 
[Public Health Agency of Canada, 2003; Sher, 1999]. 
5.5 Human herpes virus 6 (HHV-6) 
HHV-6 is causative agent of 6th disease. It presents in children as persistent fever. It is 
generally asymptomatic in adults. Significant symptoms appear in immunocompromised 
individuals.  HHV-6 causes persistent infection and there is high prevalence of antibodies 
among blood donors. Currently donor blood is not routinely screened for HHV-6 serological 
markers [Sayers, 1994]. 
5.6 Human herpesvirus 8 (HHV-8) 
HHV-8 is now associated with Kaposi’s sarcoma in immunocompromised individuals. 
Though it is transmitted through organ/bone marrow transplantation, there is lack of 
evidence of its transfusion through blood. Serological screening of blood donors is not 
recommended [Engels et al., 1999]. 
5.7 West Nile virus 
West Nile Virus (WNV) is a mosquito borne RNA virus of Flavivirus family. It is an 
important and emerging transfusion transmitted agent in North America. It was first 
isolated in 1937 from samples obtained in Uganda. It appeared in New York in 1999. This 
RNA virus can be detected by NAT. In 2002, 4200 cases of WNV were reported to centre for 
Disease Control and Prevention (CDC) and by 2003, number had risen to 9858. Most of 
WNV (80%) cases either remain asymptomatic or have only minor flu-like symptoms. In 
minority of cases (0.6%) patient can have fatal meningitis or encephalitis, especially in 
immune-compromised/elderly patients. In 2002, 23 cases of transfusion- and four cases of 
organ-transmitted WNV infection were reported and WNV-specific NAT testing was 
implemented as routine screening in the USA in 2003. No transfusion transmitted WNV case 
has been described in Europe [Bihl et al., 2007]. ` 
5.8 Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease (CJD and VCJD) 
Creutzfeldt-Jakob is a form of human transmissible spongiform encephalopathy. It is 
characterised by mental deterioration, cerebellar dysfunction, involuntary movements and 
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psychiatric disturbances. It occurs at a rate of 1 per million population annually. 
Transmission of CJD through blood is not established or ruled out. 
Variant CJD is human form of bovine spongiform encephalopathy. It is spread through 
consumption of contaminated meat of infected cattle. 
At present screening of blood donors for CJD as well as VCJD is not recommended. 
6. Bacterial contamination 
With improvement in screening methods for transfusion transmitted viral infections, 
relative risk for blood transmitted bacterial infections has increased. Approximately 57% of 
all Transfusion Transmitted infections and 16% of transfusion related deaths have been 
associated with bacterial contamination. Blood components may be contaminated with 
bacteria at many stages of preparation, including blood collection, processing, pooling, and 
transfusion. Bacteria may enter into blood components from many sources: donors' 
bacteremia, exposure to donor skin bacteria by venipuncture, contaminated bags and 
infected environment of blood banks or hospitals. The load of bacteria is determined by the 
storage time. Platelet units that are stored over 3 days and red cell units that are stored over 
21 days are strongly associated with an increased risk of bacterial reactions. 
Packed RBC’s and FFP are stored at cold temperatures, so they are not common sources of 
bacterial contamination. Some gram negative bacterias like Yersinia, Serratia, Acinetobacter, 
Pseudomonas, and Escherichia species can grow at temperatures as low as 1- 6° C and can 
therefore be transmitted through packed red cells [Dzieczkowski et al, 2008]. 
Platelet concentrates are stored at room temperature and are more likely to contain the skin 
contaminants including coagulase-negative staphylococci. Both staphylococcus and 
streptococcus infections can be transmitted through stored platelets. It is estimated that 1 in 
1,000-2,000 platelet component is contaminated with bacteria. Risk of death is 1 in 17,000 
cases of sepsis associated transfusion with RDP’s (random donor platelets) and 1 in 61,000 
when transfused platelets by apheresis. 
Recipients of blood contaminated with bacteria may develop fever with chills, followed by 
development of septic shock, DIC and death. Symptoms may develop within minutes of 
initiation of transfusion or may take several hours. The course may be abrupt, fast and 
fulminant. When reaction is suspected, transfusion should be immediately stopped. Broad 
spectrum antibiotics should be stopped. Shock should be treated. Blood bank should be 
notified. Blood component bag should be sent for Gram staining and culture. 
6.1 Syphilis 
Syphilis is caused by infection with Treponema pallidum. It is spread primarily through sexual 
contact. T. Pallidum can also be transmitted by vertical transmission from mother to fetus or 
through blood if donor is already infected. Its transmission through transmission has become 
extremely rare after implementation of the serological tests for antibodies to T. Pallidum. 
6.2 Rocky mountain spotted fever (RSMF) 
It is a severe tick borne disease caused by Rickettsia ricketsii – a bacterium. The disease is 
endemic in most part of the United States. RMSF is characterized by the sudden onset of 
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moderate to high fever, which normally persists for 2-3 weeks, if untreated. Other typical 
symptoms include headache, myalgia, and petechial rash, and early RMSF may be confused 
with meningitis. RMSF is transmitted mainly through the bites of infected ticks. Currently, 
no specific questions or assays are used for screening and testing of serologic markers of R. 
rickettsii in blood donors. 
6.3 Malaria 
Malaria is an important parasitic infectious disease worldwide. Malaria is endemic in 
tropical and sub-tropical regions in Asia and Africa, with up to 300 million infections and 
one million deaths annually. It is caused by four species of Plasmodium, namely vivax, 
ovale, malariae and falciparum. P. Falciparum may result in severe complications and/or 
death. It is spread primarily by bite of the infected female Anopheles mosquito. It can also 
be transmitted from infected mother to her fetus or from an infected blood donor to the 
recipient. Patients of chronic hemolytic anemia, as of thalassemia are on regular packed 
RBC’s infusion and are at risk for malaria. 
6.4 Chagas disease 
The etiological agent is a protozoan parasite – Trypanosoma cruzi. It is endemic in Central 
and South America and parts of Mexico. Acute infection presents as fever, 
lymphadenopathy, hepatosplenomegaly, cardiomegaly and mega-esophagus. T. cruzi is 
transmitted from an infected vector to a person through feces deposited on the skin at the 
time of bite. The agent can also be transmitted vertically from mother to infant and through 
blood transfusion and organ transplantation. 
Donors who were born or have lived in endemic areas for more than 1 year are more 
likely to be positive for T. cruzi antibodies. The majority of patients diagnosed with 
Transfusion Transmitted Chagas disease in North America have been found to be 
immunosuppressed. 
Screening methods, such as inquiry about travel history and testing for serologic markers, 
are neither sensitive nor specific enough to effectively identify asymptomatic blood donors. 
Leukodepletion may reduce the risk of transfusion transmitted Chagas' disease [Leiby, 
2000]. 
7. Toxoplasmosis 
Toxoplasmosis is a zoonosis caused by Toxoplasma gondii, a parasite that is hosted in cats and 
dogs and has three forms - trophozoites, cysts and oocysts. About 5 million people are 
affected worldwide. The infection is usually asymptomatic or causes minor symptoms like 
fever, malaise and cutaneous rash. It can cause myocarditis and meningo-encephalitis in 
immunocompromised individuals; and fetal death in a pregnant female. The seroprevalence 
of antibodies to T. gondii increases with age and varies from 8% to 60%. 
It has been suggested that people who are at increased risk of toxoplasmosis, such as 
immunosuppressed individuals and pregnant women, receive T. gondii antibody-negative 
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blood components for transfusion. The universal program of leukodepletion that is 
currently carried out in Canada may reduce the risk of transfusion transmitted 
toxoplasmosis. 
7.1 Leishmaniasis 
Leishmaniasis is caused by Leishmania donovani and affects nearly 12 million people in 
tropical and subtropical areas. Acute infection is often subclinical and chronic infection 
usually leads to anemia, lymphadenopathy and hepatosplenomegaly. Transmitted usually 
by infected vector – the sandfly, it can also be transmitted by blood transfusion. Due to 
global travel of diverse population and costly testing, leishmaniasis is now prevalent in 90 
countries. Individuals returning to the US from combat zones in Iraq are currently deferred 
for blood donation for one year [Bihl et al., 2007].   
7.2 Babesiosis 
It is a zoonotic disease caused by Babesia microti. Babesia is a genus of protozoal piroplasm. 
Usually patient is asymptomatic or has mild symptoms like fever and headache. Patient 
may have severe anemia and hemolytic anemia. The disease is severe in infants, older 
patients, splenectomized and immunocompromised individuals. Usual transmission is by 
bite of deer ticks. There is low risk of transmission through blood. Effective screening 
methods for blood donors are not available. 
8. Nematodes – Microfilariasis 
Filaria is a disease seen in tropical countries like India in Asia. Microfilariae present in a 
donor’s blood having filaria can be transmitted by blood transfusion. These may circulate in 
the recipient's blood but do not develop into adult worms. Mortality is not documented 
after such incidence but it may give rise to morbidity in transfusion recipients in terms of 
allergic reaction [Choudhary et al., 2003]. Transfusion associated filarial infection can 
increase morbidity in endemic areas. Blood donors with active history of filarial infection 
should be deferred from donating blood. Filarial antigen detection test may be employed as 
a screening test for blood donors. 
9. Prevention of transfusion transmitted infections 
1. Transfusion of non-infected blood/blood products: Etiological agent present in 
donor’s blood can escape detection. Development of antibodies against the etiological 
organism takes time. So screening tests dependent on antibody detection fail to detect 
infection in early period. After use of NAT testing, this window period for HIV, 
Hepatitis B and Hepatitis C is reduced. 
2. Encouraging voluntary blood donation: In developed countries, the majority of blood 
donors are voluntary, whereas in developing countries, majority of blood donors are 
replacement donors. The incidence of blood transmitted infections is much lower in the 
countries having majority of transfusions from voluntary donation. 
3. Donor deferral: Current strategies to prevent transfusion transmitted malaria are based 
on risk group assessment and donor deferral for 4-12 months for visitors from low 
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endemic areas to high endemic countries and 3-5 years (or permanently) for donors 
with a history of residence in an endemic area. However, this policy may lead to 
unaffordable loss of blood donation. That is why the policy of travel based risk 
assessment is combined with serological screening tests in some countries. 
4. Immunization: Hepatitis B should be prevented by vaccination. HIV vaccine is being 
developed. Hepatitis C vaccine is not available at present. More vaccines should be 
developed to prevent transfusion of transmitted infections. 
5. Prevention of infection of stored blood/blood products: Storage system in blood bank 
has to provide infection free environment. 
6. Use of infection free equipment for transfusion: Use of disposable syringes/needles 
etc will decrease the risk of transmission of infections. 
7. Education: HIV transmission can be prevented by increasing awareness, and first AID 
education of health workers. Unnecessary blood donations should be avoided to 
decrease the risk factor.   
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